Featured Speakers:
Michael Amos, Ph.D., Scientific Advisor, Chemical Science & Technology Laboratory, National Institute of Standards & Technology Measurement; ex-officio member, Secretary’s Advisory Committee on Genetics Health and Society (SACGHS), Department of Health and Human Services
Samuel C. Blackman, M.D., Ph.D., Associate Director, Experimental Medicine/Oncology, Merck Research Laboratories
Massimo Cristofanilli, M.D., FACP, Professor and Chairman, Department of Medical Oncology; G. Morris Dorrance Jr. Endowed Chair in Medical Oncology, Fox Chase Cancer Center
Viswanath Devanarayan, Ph.D., Director, Global Exploratory Statistics, Abbott Laboratories
Giora Feuerstein, M.D., President, FARMACON, LLC, Translational Medicine Drug Discovery and Development Consulting; formerly Assistant Vice President and Head, Discovery Translational Medicine, Wyeth Research
Mark Fidock, Ph.D., Head, Quantitative Biomarkers, Research Enabling Group, Pfizer Ltd.
Felix W. Frueh, Ph.D., Vice President, Research & Development, Personalized Medicine, Medco Health Solutions, Inc.
Andrew Grupe, Ph.D., Senior Director, Pharmacogenomics R&D, Celera Corporation
Darren Hodgson, M.D., Biomics Advisor, Oncology and Infection Therapy Area, AstraZeneca
Dave S. B. Hoon, Ph.D., Director, Department of Molecular Oncology, John Wayne Cancer Institute
Francis Kalush, Ph.D., Network Leader, Diagnostics & Personalized Medicine, CDRH, U.S. Food and Drug Administration
Aaron B. Kantor, Ph.D., Chief Scientific Officer, Research and Development, Immune Tolerance Institute
Joe Keenan, Head, Sales & Marketing, Argutus Medical Ltd.
Geert J.C.M. Kolvenbag, M.D., Ph.D., Global Product Vice President, Oncology, AstraZeneca Pharmaceuticals, Inc.
Myla Lai-Goldman, M.D., Chief Executive Officer, CancerGuide Diagnostics, Inc.
Thomas M. Li, Ph.D., Chief Technology Officer and Senior Director, Technology Management, Roche Diagnostics
Michael N. Liebman, Ph.D., Managing Director, Strategic Medicine, Inc.
Robert McCormack, Ph.D., Director, Technology Assessment, Ortho Clinical Diagnostics, Veridex, LLC
Madhu Mondal, Ph.D., Head, Protein and Analytical Toxicology Laboratory, Investigative Toxicology/Preclinical Safety, Novartis Institutes for BioMedical Research, Inc.
Margaret Piper, Ph.D., MPH, Director, Genomics Resources, Technology Evaluation Center, Blue Cross Blue Shield Association
Bruce Quinn, M.D., Ph.D., Senior Health Policy Specialist, Foley Hoag; Former California Medical Director, NHIC
Donna Roscoe, Ph.D., Scientific Reviewer, DIHD/OIVD/CDRH/FDA
Allen D. Roses, M.D., Jefferson-Pilot Professor, Neurobiology and Neurology; Director, Deane Drug Discovery Institute, Duke University
Yaping Shou, M.D., Ph.D., Director, Oncology Biomarkers and Imaging, Biomarker Project Leader-Tasigna, Novartis Institutes for BioMedical Research
Shabnam Tangri, Ph.D., Director, Clinical Science and Technology, Biogen Idec
John Wagner, M.D., Ph.D., Vice President, Clinical Pharmacology, Merck Research Laboratories
Yaning Wang, Ph.D., Team Leader, Pharmacometrics, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
David Wholley, Director, Biomarkers Consortium, Foundation for the NIH
Hans Winkler, Ph.D., Senior Director & Global Head, Oncology Biomarkers, Johnson & Johnson Pharmaceutical R&D